NASDAQ: CLLS - Cellectis S.A.

Yield per half year: +96.24%
Sector: Healthcare

Share chart Cellectis S.A.


Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

More details
It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia Therapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Main settings

Выручка 0.0152
EBITDA -0.1167
Число акций ао 0.04555 млрд
P/S 57.43
P/BV 1.6236
Цена ао 2.57
ISIN US15117K1034
Change price per day: 0% (2.61)
Change price per week: -5.09% (2.75)
Change price per month: +2.76% (2.54)
Change price per 3 month: -5.78% (2.77)
Change price per half year: +96.24% (1.33)
Change price per year: +27.94% (2.04)
Change price per year to date: -25.21% (3.49)

All parameters ⇨



Title Value Grade
P/S 57.43 3
P/BV 1.6236 10
P/E 0 0
EV/EBITDA -3.58 0


Title Value Grade
ROA, % -30.68 0
ROE, % -58.18 0


Title Value Grade
Div yield, % 0 0
DSI 0 0


Title Value Grade
Debt/EBITDA -0.9231 10

Growth impulse

Title Value Grade
Profit growth, % 0.86 0
Share price growth, % 0 0
Dividend growth, % 0 0

Main owners

Institutions Volume Share, %
Long Focus Capital Management, LLC 4487293 6.25
Capital International Investors 1848804 2.58
Credit Suisse Ag/ 1438255 2
Baillie Gifford and Company 816643 1.14
Principal Financial Group, Inc. 399627 0.56
Macquarie Group Limited 226875 0.32
KBC Group NV 163447 0.23
Oppenheimer & Company Inc. 133143 0.19
Morgan Stanley 76225 0.11
LPL Financial LLC 72187 0.1

Similar companies

Company management

Head Job title Payment Year of birth
Dr. Andre Choulika Ph.D. Co-Founder, CEO & Director 744.02k 1965 (59 years)
Dr. Bing C. Wang M.B.A., Ph.D. Chief Financial Officer N/A 1977 (47 years)
Valerie Cros Principal Financial Officer & Principal Accounting Officer N/A
Mr. Jean Charles Epinat Chief Technological Officer N/A
Dr. Philippe Duchateau Ph.D. Chief Scientific Officer N/A 1963 (61 year)
Mr. Stephan Reynier M.Sc. Chief Regulatory & Pharmaceutical Compliance Officer N/A 1969 (55 years)
Ms. Marie-Bleuenn Terrier General Counsel & Secretary of the Board of Directors N/A 1982 (42 years)
Pascalyne Wilson Director of Communications N/A
Ms. Kyung Nam-Wortman Executive VP & Chief Human Resources Officer N/A 1970 (54 years)
Dr. David j. d. Sourdive Ph.D. Deputy CEO, Executive VP of CMC & Manufacturing and Director 528.92k 1967 (57 years)

About company

Address: France, Paris, 8. rue de la Croix Jarry - open in Google maps, open in Yandex maps
Phone: +tel:33181691600